Results 141 to 150 of about 6,967 (165)

Tolvaptan

Nature Reviews Drug Discovery, 2009
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
Jalal K, Ghali, Bashar, Hamad, Uma, Yasothan, Peter, Kirkpatrick   +3 more
openaire   +4 more sources

ChemInform Abstract: Aminocarbonylation Route to Tolvaptan.

ChemInform, 2007
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Takuya Furuta, Shinji Aki, Takao Nishi, Yasuhiro Torisawa, Jun-ichi Minamikawa   +4 more
openaire   +4 more sources

Analysis of tolvaptan non‐responders and outcomes of tolvaptan treatment of ascites

Journal of Gastroenterology and Hepatology, 2018
AbstractBackground and AimThe goals of the study were to identify an effective treatment for ascites and to examine the influence of tolvaptan on outcomes by investigating non‐responders to tolvaptan and comparing outcomes of hepatic cirrhosis in patients treated with and without tolvaptan.MethodsIn Study 1, of 145 patients with hepatic cirrhosis who ...
Takuya Iwamoto, Masaki Maeda, Issei Saeki, Isao Hidaka, Kunihiko Tajima, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida   +7 more
openaire   +3 more sources

Results of the use of tolvaptan [PDF]

European Journal of Hospital Pharmacy, 2012
Background Tolvaptan is indicated to treat syndrome of inappropriate antidiuretic hormone secretion (SIADH). Purpose To describe and assess the use of tolvaptan in a tertiary hospital. Materials and methods An observational and retrospective study was conducted on patients treated with tolvaptan.
M Vuelta Arce, L Sánchez Parada, L Canadell Vilarrasa, L. Castillo Palomares, S Jornet Montaña, L. Sánchez-Pacheco Tardón, M Canela Subirada, J Torrent Pou   +7 more
openaire   +1 more source

Update on tolvaptan for the treatment of hyponatremia

Expert Review of Pharmacoeconomics & Outcomes Research, 2012
Tolvaptan is a member of a new class of drugs, called the vaptans, that antagonize receptors of the neurohormone arginine vasopressin. From a clinical perspective, tolvaptan has been shown to be efficacious in the treatment of hyponatremia, whether it is idiopathic or disease related, and it may have a more favorable benefit/risk profile than other ...
Melissa Lingohr-Smith, Joseph F. Dasta, Jay Lin, Rudell Christian, Irving B Cassidy, Jun R Chiong, Keith Friend   +6 more
openaire   +2 more sources

Tolvaptan

Drugs, 2010
Tolvaptan is an orally administered, nonpeptide, selective arginine vasopressin V(2) receptor antagonist that increases free water clearance, thereby correcting low serum sodium levels. SALT-1 and -2, two identical, randomized, double-blind, placebo-controlled, multicentre trials, included patients with hypervolaemic or euvolaemic hyponatraemia (serum ...
openaire   +3 more sources

Tolvaptan: øHow is it used?

European Journal of Hospital Pharmacy, 2012
Background Tolvaptan is an orally active vasopressin V2-receptor antagonist used to treat hyponatremia associated with congestive failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Hyponatremia ( Purpose Our aim is to analyse the use of the drug, benefit and adverse effects, checking if the prescription complies with
C. Ridaura-Rivera, José Luis Poveda-Andrés, M Montero-Hernández, I. Font-Noguera, M. Galiana-Sastre, C. Jordan de Luna, M.J. Fernández-Megía   +6 more
openaire   +2 more sources

Tolvaptan: A New Therapeutic Agent

Reviews on Recent Clinical Trials, 2011
Tolvaptan is a new agent in the treatment of normovolemic and hypervolemic hyponatremia. It is a V(2) receptor antagonist inducing free water diuresis. It has been recently approved in USA and Europe for the treatment of hyponatremia associated with SIADH, cirrhosis as well as heart failure, while in hypovolemic hyponatremia its use is contraindicated.
Polichronis Alivanis, Georgios Aperis
openaire   +3 more sources

Nonclinical Safety Profile of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
In the present study, the nonclinical safety profile of tolvaptan was evaluated.A series of safety pharmacology and toxicology studies were performed in vitro and in mice, rats, dogs, rabbits and guinea pigs.In safety pharmacological studies, tolvaptan had no adverse effects on the central nervous, somatic nervous, autonomic nervous, smooth muscle ...
Katsumi Morishita, Toshiyuki Shiragiku, Hajime Morimoto, Tadashi Senba, Takumi Awogi, Tohru Uesugi, S Fujita, Atsushi Ozaki, Norio Ito, Masaya Miyatake, Naoto Nakagiri, Nobuya Ishiharada, Masanao Umezato, Akihide Oi, Hironobu Ishiyama, Eiji Hosoki   +15 more
openaire   +3 more sources